What are drugs originally? From diabetes aids to weight management tools
Semaglutide, originally developed by the Danish pharmaceutical company Novo Nordisk, belongs to the class of GLP-1 receptor agonists and was initially used for glycemic control in patients with type 2 diabetes. Its mechanism of action mainly includes promoting insulin secretion, inhibiting glucagon release, slowing gastric emptying, and enhancing satiety.
These mechanisms of action not only help stabilize blood sugar but also bring additional benefits—reduced appetite and food intake, leading to gradual weight loss. In 2021, the U.S. FDA officially approved high-dose semaglutide for long-term weight management in overweight or obese individuals, marketed under the brand name Wegovy, which garnered global attention.
However, it is important to note that this indication is strictly limited to obese patients with a BMI ≥ 30, or those with a BMI ≥ 27 and accompanied by metabolic syndrome such as hypertension and hyperlipidemia. In other words, semaglutide is essentially part of a chronic disease treatment plan, rather than a "quick weight loss secret" for healthy individuals.
The pharmacological effects are indeed significant. A clinical study showed that after 68 weeks of use, the subjects' average weight decreased by 14.9%, with some individuals experiencing a decrease of over 20%. However, this is predicated on professional assessment and strictly controlled medical intervention, which should not be underestimated.
Behind the online phenomenon: Why is the pursuit of weight loss turning into "drug dependence"?
Social media spreads information far faster than medical literature. Short video platforms, celebrity interviews, and personal experience sharing all mention "losing 10 pounds in a month after taking Smegglutide" and "losing weight without feeling hungry or craving anything, even while lying down," quickly igniting the public's impulse to use medication amidst their weight loss anxieties.
In particular, the positive reviews describing diets as "not appealing anymore," "unable to drink milk tea," and "only eating one meal a day" have led many to mistakenly believe that this is a safe and magical "dieting shortcut." Pharmacies have also seized the opportunity to launch "Simegrapeptide injection pens," and there have even been online gray market transactions involving sales without prescriptions and "one-stop delivery."
Why are people so eager for "weight loss through medication"? There are three main reasons:
First, there's the psychological fatigue from long-term failed weight loss attempts. The difficulty in sticking to diets and the slow results of exercise trap many people in a vicious cycle of fluctuating weight and self-doubt, leading them to seek external help.
Secondly, there is a blind spot in understanding "health side effects." People see the significant weight loss results but ignore the systemic effects of the drug on the gastrointestinal, endocrine, and emotional systems.
Third, social media information is distorted. Many videos of "successful weight loss" fail to disclose the true background, such as whether there are underlying medical conditions, whether there is professional guidance, and whether there is a rebound, leading the public to believe the myth of "easy weight loss".
However, smegglutinin is essentially a potent agonist that intervenes in human metabolism and appetite regulation, unlike the mild effects of slimming coffee or health tea, and its risks should not be underestimated.
Adverse reactions have surfaced: What risks are hidden beyond weight loss?
Although the marketing studies of smegglutide have confirmed its effectiveness in weight control, a series of potential adverse reactions are also increasingly attracting the attention of the medical community.
I. Gastrointestinal discomfort is the most common side effect.
Users often experience symptoms such as nausea, vomiting, diarrhea, and constipation. Although these reactions are mild to moderate, they significantly impact quality of life. Some people even experience electrolyte imbalances or decreased physical strength due to their inability to eat.
II. Increased risk of gallbladder disease
Studies have shown a positive correlation between GLP-1 agonists and the incidence of gallstones and cholecystitis. Rapid weight loss itself also increases the risk of cholesterol deposition in the bile ducts.
III. Hypoglycemia and Insulin Interference
Although it does not directly induce hypoglycemia, it may exacerbate hypoglycemic reactions in patients who are using insulin or sulfonylurea hypoglycemic drugs, especially the elderly.
IV. Potential for causing thyroid C-cell lesions
In animal studies, smegglutinin has been linked to the risk of thyroid C-cell tumors. Although there is no conclusive evidence in humans, some guidelines have listed it as a contraindication.
V. Risks of psychological dependence and eating disorders
Some people experience a rebound effect once they stop taking the medication, developing a "behavioral dependence" on the drug; some even develop a fear of eating, progressing to mild anorexia or mood eating disorder.
Medicine does not oppose the use of semaglutide to treat obesity, but only with professional evaluation and continuous monitoring. Focusing solely on "weight loss" while ignoring the "costs" can easily lead to the trap of harmful medications.
Not everyone can use it: Which groups should use it with more caution or even avoid it altogether?
Not everyone is suitable for using smegglutide for weight loss. According to relevant drug instructions and medical consensus, the following groups should pay special attention:
Pregnant women and breastfeeding women
There are insufficient studies to assess its effects on the fetus or infant. It is recommended to stop taking the medication at least two months before pregnancy and it is contraindicated during breastfeeding.
Patients with a family history of medullary thyroid carcinoma
Because the drug may affect C cells, it is recommended that people with such a medical history avoid using it completely.
Those with a history of pancreatitis
Smegglutinin may cause pancreatitis or worsen pre-existing conditions, and its use should be approached with extreme caution.
Patients with severe gastrointestinal diseases
Patients with conditions such as gastroparesis or active gastric ulcers are more prone to exacerbating their condition due to the effects of medication on gastric emptying.
Patients with mental disorders and eating disorders
Medications may affect mood and appetite control, increasing the risk of eating behavior disorders.
In addition, young women whose BMI is within the normal range but who simply want to "slim down" their face and "slimmer legs" should understand that this drug is not a "slimming and beautifying" product, but a medical tool for people with metabolic abnormalities. Use without medical indications may lead to long-term health risks.
Successfully lost weight, but health problems arose.
Ms. Wang, 29 years old, from Shanghai, works in an office at a company. She is 160cm tall and weighs 62kg. Because she was about to have her wedding photos taken, she wanted to lose weight quickly. She purchased a Smegglutide injection pen through a social media platform and, without seeking medical evaluation, injected it herself for 8 weeks, resulting in a weight loss of 7kg.
Initially, she reported "no appetite and feeling lightheaded," but by the fifth week, she began experiencing frequent nausea and stomach pain, which later developed into persistent abdominal bloating and jaundice. She was rushed to the hospital and diagnosed with drug-induced cholecystitis and mild pancreatitis. The doctor pointed out that her constitution did not meet the indications for medication, and that the dosage had been increased too quickly, causing her gastrointestinal system to be unable to adapt.
After being discharged from the hospital, Ms. Wang admitted, "I did lose weight, but I lost my quality of life and paid a huge price." She began to adjust her diet and followed the guidance of a nutritionist to restore her intestinal function, which gradually helped her get rid of the side effects.
This case is not uncommon. Currently, many people, driven by anxiety about weight loss, are "over-medicalizing" their body management, forgetting that medication is never a panacea without a price.
The bottom line for rational drug use: Standardized weight loss needs to return to a medical track.
The World Health Organization emphasizes that weight loss is a long-term behavioral intervention program that should include nutritional adjustments, exercise programs, behavioral and cognitive correction, and, when necessary, medication. As a medication, semaglutide must be used strictly and within the bounds of clinical practice.
First, a professional doctor needs to assess whether it is suitable for use.
This includes body mass index (BMI), blood sugar status, underlying medical conditions, and any drug contraindications.
II. Must accept dose-by-dose adjustment and cycle management
The clinically recommended initial dose is 0.25 mg per week, gradually increasing to a maximum of 2.4 mg, and adjusted according to tolerance.
Third, dietary and exercise interventions must be combined; otherwise, the effects will be difficult to maintain.
Medications can only "help control appetite" and cannot replace core processes such as energy consumption and muscle maintenance.
IV. Discontinuation of medication should be planned to avoid rebound and metabolic disorders.
Abrupt cessation may cause a rapid rebound in appetite; it is recommended to use behavioral interventions to facilitate a smooth transition.
Fifth, clearly define your weight loss goal as "healthy weight" rather than "extremely thin".
The goal of medical intervention is to improve metabolic indicators and reduce the risk of chronic diseases, rather than to pursue a gaunt appearance.
Weight loss is never a shortcut, but a reconciliation with your body, diet, and mind. Smegglutinin can be a supporting ingredient in this battle, but it's by no means a magic bullet. Only by acknowledging the true nature of health can you go further.